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ABSTRACT
SYDNEY REBECCA HARRISON: Method Development and Pharmacokinetic Study of
JY08, A Dual Opioid-NPFF Receptor Ligand
(Under the direction of Dr. Bonnie A. Avery)
Within the United States and worldwide, a rapidly developing public health crisis is at
hand due to the abuse of opioids. With high percentages of Americans experiencing both
acute and chronic pain and limited treatment routes, opioid analgesics are highly
prescribed in clinical practice. These drugs act on central nervous system to activate
opioid receptors in regions of the brain regulating pain and reward. However, these
compounds are associated with many unwanted adverse effects including tolerance,
dependence, hyperalgesia, and addiction. Thus, there is a need to for the development of
new drug candidates that can serve as analgesics for long-term use without the unwanted
side effects. The neuropeptide FF (NPFF) system is known to modulate the antinociceptive properties of the opioid system. With this knowledge, the development of
compounds that can serve both as a NPFF receptor antagonist and an opioid receptor
agonist has become a recent focus in analgesic drug discovery and development. The
novel compound JY08 was designed as a dual-activity ligand that acts as an agonist at the
mu-opioid receptor and antagonist at the NPFF receptor in order to combat the tolerance
and hyperalgesia conditions commonly associated with long-term opioid use. Ultra-high
performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)
bioanalytical methods were developed for the quantification of JY08 through
pharmacokinetic, solubility, and metabolic stability studies.
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1.

INTRODUCTION

1.1 The opioid epidemic
The United States is currently in the midst of an ongoing opioid epidemic. On October
26, 2017, President Donald Trump declared the national opioid crisis as a public health
emergency (1). The US has experienced a 17-year increase in opioid overdose deaths
due to both prescription and illicit opioids (2). Weiner et al. identified three driving
forces associated with the growing opioid epidemic: the moral imperative for providers to
treat pain and relieve suffering, the under-treatment of pain, and pharmaceutical
industries (3). The epidemic’s antecedents can be traced back to the late 1990s during
which the American Pain Society recognized pain as the fifth vital sign (4). As a result of
these efforts and the associated moral imperative, physicians became more liberal in the
prescription of opioids for chronic, noncancer pain (4). As pain was being adopted as the
fifth vital sign, OxyContin was first hitting the markets. It was soon to become top 30%
of total analgesic sales and become the most abused prescription opioid on the market
(4). The manufacturer, Purdue Pharma, was assertively marketing OxyContin while
distorting the risk for addiction associated with the drug (5). Mass prescription of opioid
analgesics for acute and chronic pain soon followed these events, contributing to much of
the crisis currently being experienced in the United States.
As the leading cause of US injury-related death, opioid overdoses were attributed to over
42,000 deaths in 2016, five times higher than experienced in 1999 (6). On average, 115

Americans die each day due to opioid abuse and misuse (2). However, overdoses are not
the only risk related to opioids; the abuse, misuse, and addiction related to these drugs are
each hallmarks of the current epidemic. In 2014, 2 million individuals claimed to abuse
or be dependent on prescription opioids (7). Additionally, over 1000 patients are treated
each day in emergency departments for opioid misuse (8). Coinciding with these
increases in use, increases in the diagnosis of opioid-use disorder have been observed
with 2.0 million people over the age of 12 years being affected in 2016 (9). Factor in the
increased risk of infectious disease due to unsafe injecting and other psychiatric
comorbidities, the US is currently experiencing one of the greatest public health crises of
its time. The opioid crisis reaches beyond the United States, with 29.5 million people
globally suffering drug use disorders—the majority of these due to opioids (10).
Recently the National Institute of Health (NIH) has launched an initiative to address this
public health crisis focusing on three areas: overdose-reversal interventions, treatments
for opioid addiction, and non-addictive treatments for chronic pain (11). With the
majority of opioid abusers starting their path to dependence and addiction through
prescription medications, the population that depends on opioid analgesics for daily
living are particularly vulnerable in this epidemic.
1.1.1

Chronic pain

As defined by the International Association for the Study of Pain (IASP), pain is “an
unpleasant sensory and emotional experience associated with actual or potential tissue
damage or described in terms of such damage” (12). The IASP defines chronic pain as
“pain that persists beyond normal tissue healing time, which is assumed to be three
months” (12). Chronic non-cancer pain is a multifactorial condition that can be attributed
2

to neuropathic pain, fibromyalgia, lumbar pain, osteoarthritis, and many others. Chronic
pain is reported to affect approximately 30% of Americans and 20% of people worldwide
(11,13) The condition is also the cause for 15-20% of physician visits (13). The
recommended first line of treatment for chronic pain includes antidepressants,
anticonvulsants, and topical lidocaine (11). The IASP recommends opioids as a secondline chronic pain treatment (11). However, the use of opioids for the treatment of chronic
pain is very common, with an estimated 20% of patients presenting with pain or a painrelated condition receiving an opioid prescription (14). Long-term use of opioids has
been associated with many adverse effects including gastrointestinal issues, addiction,
tolerance, cardiovascular complications, and hyperalgesia. Because of current treatment
limitations and the US Congress declaration of 2000-2010 Decade of Pain and Control
Research, the prescription of opioid analgesics for pain management has been rapidly
rising in clinical practice. Addressing the needs of patients with chronic pain through the
development of safer, more effective treatments is a necessary step in ultimately
overcoming the opioid crisis.
1.2 The opioid system
The opioid receptor system consists of three subtypes widely distributed throughout the
CNS and PNS: mu, kappa, and delta. Opioid medications primarily exert their analgesic
effects through binding to the mu-opioid receptors (15). Within the CNS, mu-opioid
receptors are present at high concentrations in areas regulating nociception
(periaqueductal gray, thalamus, cingulate cortex, and insula), pain-induced emotional
response (amygdala), and reward pathways (ventral tegmental area and nucleus
accumbens) (15). Repeated use of opioids is known to be accompanied with an array of
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unwanted adverse effects. Tolerance is a primary effect of frequent opioid use.
Continuous administration of opioid agonists leads to a suppression of endogenous
opioids and decrease in analgesic efficacy. This phenomenon is often observed in
individuals with chronic pain disorders or opioid use disorders, two of the populations
most dependent on opioid analgesics. The physiological process of tolerance involves a
reduction in endogenous opioid production in the body. Thus, higher doses of exogenous
opioids are needed with each subsequent administration in order to achieve the same
analgesic effect, and for those suffering from opioid use disorder, often to reach the same
euphoric effect. Tolerance also involves the desensitization and internalization of opioid
receptors, further decreasing agonist efficacy (16). Opioid-induced hyperalgesia (OIH)
has also been recognized as an issue due to long-term opioid use. Though commonly
confused with tolerance, OIH is a separate phenomenon associated with opioid use. This
disorder leads to an increased sensitivity to pain stimuli. Thus, patients taking opioid
analgesics for the treatment of pain will experience increasing pain sensations, resulting
in the use of higher doses of opioids as with tolerance. The mechanism of OIH is thought
to be a counter-balance by endogenous pronociceptive peptides such as dynorphin A and
neuropeptide FF. Neuropeptide FF (NPFF) and its receptors have been found to play a
role in pain transmission, interacting with the opioid system (17). These anti-opioid
modulating systems are observed to be overstimulated during chronic opioid
administration. Dual ligands for the opioid and NPFF receptors have recently become a
target of drug discovery and design in the development of treatments for chronic pain
without the classic opioid-related adverse effects.
1.2.1 Neuropeptide FF
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Neuropeptide FF belongs to the RF-amide peptide family and interacts with two Gi
protein-coupled receptors, NPFFR1 and NPFFR2. These receptors are distributed
throughout the central nervous system (CNS) with high density in the spinal dorsal horn
and the periaqueductal gray, areas involved in pain modulation (18). The NPFF signaling
system has is bimodal in pain perception, producing both pro-nociceptive and antinociceptive effect (17). The experienced effect is dependent upon the route of
administration. Intra-thecal administration of NPFF is shown to potentiate opioid
analgesia. In contrast, intra-cerebroventricular administration of NPFF is shown to
decrease morphine-induced analgesia in rats (17).
1.3 JY08, a novel dual NPFF/opioid receptor ligand
JY08 was developed by the McCurdy research group at the University of Mississippi
Department of BioMolecular Sciences. The compound was developed to create a dualactivity drug that acts as an analgesic while eliminating tolerance or hyperalgesic effects.
JY08 is a non-peptide small-molecule with the classic guanidine and phenyl components
of NPFF receptor antagonists. Structure-activity relationship (SAR) studies analyzing the
effect of NPFF’s C-terminal amino acids on NPFFR binding and activity have shown that
the amidated residues of phenylalanine and arginine on NPFF are crucial for activation of
anti-opioid effects (19). Thus, the guanidine and phenyl groups on JY08 are able to
mimic these interactions while maintaining low molecular weight and size to increase
bioavailability. Additionally, the absence of a peptide bond prevents protease cleavage of
the NPFF antagonist. A piperidine core was incorporated into the molecule based on past
mu-opioid agonists developed by the McCurdy research group to facilitate opioid
receptor binding. Based on the structure and Lipinski’s parameters regarding oral
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bioavailability, JY08 meets 3 of 4 criteria and is predicted to be orally bioavailable
(Table 1). The calculated LogP of JY08 also indicates the compound to have high
lipophilicity, showing potential for JY08 to cross the blood brain barrier. These
predications are to be tested later through in vivo studies.

Figure 1. Structure of JY08

Lipinski’s Rules
 500
5
 10
0 < LogP < 5

Molecular weight
Number of hydrogen bond donors
Number of hydrogen bond acceptors
Calculated LogP

JY08
402.59
3
4
5.305

Table 1. Prediction of Oral Bioavailability

JY08 was tested in multiple cell assays. When tested against the delta-, kappa-, and muopioid receptors, it exhibited a Ki of 1763  215, 649.9  117.8, and 34.29  5.38 nM,
respectively. JY08 also exhibited an EC50 of 721.6  195.0 nM for the mu-opioid
receptor.
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1.4 Preclinical studies of JY08
Pharmacokinetics and drug metabolism are essential components of the drug
development process. In order to successfully develop a drug candidate, the
pharmacokinetic principles of absorption, distribution, metabolism, and elimination
(ADME) must be analyzed. Key parameters for pharmacokinetic analysis include oral
bioavailability (F), half-life (t1/2), volume of distribution (Vd), and clearance (CL). These
screening processes can eliminate drug candidates that exhibit poor absorption, extensive
first-pass metabolism, and/or too long/short half-lives. However, these processes can
also identify drug candidates that have good oral bioavailability and distribution to target
tissues. Thus, both in vitro and in vivo pre-clinical studies are necessary for the
development of successful drug candidates for potential use in humans.
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2.

METHODS

2.1 Materials and reagents
The compound (JY08) and internal standards (WA475, CM398) were provided by Dr.
Christopher McCurdy, initially synthesized by Dr. McCurdy’s research group,
Department of BioMolecular Sciences, The University of Mississippi. LC-MS grade
methanol, acetonitrile, and water were purchased from Fisher Scientific (Fair Lawn, NJ,
USA). Formic acid and trifluoroacetic acid were obtained from Mallinckrodt Baker Inc.
(Phillipsburg, NJ, USA). TRIS, magnesium chloride, and potassium phosphate were
obtained from Sigma-Aldrich (St. Louis, MO, USA). NADPH was purchased from MP
Biomedicals (Solon, OH, USA). Rat liver microsomes were purchased from XenoTech
(Lenexa, KS, USA). Rat plasma was purchased from VWR (Suwannee, GA, USA).
2.2 Instrumentation and analytical conditions
Two LC-MS/MS instruments were used for analysis of the compounds. The
instrumentation from Thermo Scientific was used for the provided calibration curve,
metabolic stability studies, and solubility studies. Waters instrumentation was used for
the analysis of pharmacokinetic studies in rats. Separate methods for JY08 and the
respective internal standards (IS) were developed on each instrument to ensure validated
analysis. Internal standards were chosen based on their chemical structure and function,
which is preferably similar to the structure and function of JY08. The IS should be
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compatibile with the LC-MS/MS method developed for JY08 and produce strong,
consistent signals within the run time.
2.2.1

Method development on Thermo Scientific UPLC-MS/MS systems

Accela ultra-high performance liquid chromatography system (Thermo Scientific,
Waltham, MA, USA) equipped with a quaternary solvent manager, vacuum degasser,
thermostatted column sleeve, an auto-sampler, a Waters Acquity UPLC CSH C18
column (1.7 L, 2.1 x 100 mm; Milford, MA, USA)and was used for chromatographic
separation. The mobile phase was a gradient method (Table 2) using 0.02% v/v
trifluoroacetic acid in water and 0.02% v/v trifluoroacetic acid methanol. The mobile
phase was pumped at a flow rate of 0.3 mL/min for a run time of 3.5 minutes. The
column temperature was maintained at 40oC and the injection volume was 10 L. Two
washes were used in between runs to prevent carryover and sample contamination: strong
needle wash (methanol) and weak needle wash (50:50 methanol: water (0.01% v/v formic
acid)). Weak needle washes typically have similar compositions to the mobile phase and
are used following the strong needle wash to ensure the strong wash is flushed from the
needle and sample loop.
Time (min)
0
2
2.5
3
3.5
Table 2. UPLC-MS/MS Gradient 1

%A
95
5
5
95
95

%B
5
95
95
5
5

*A- 0.02% TFA in Water *B-0.02% TFA in Methanol

Mass spectrometric (MS) analysis was performed using TSQ Quantum Access MAX
(Thermo Scientific, Waltham, MA, USA) equipped with an electro-spray ionization (ESI)
source. The detection was achieved with ESI positive ionization using multiple reaction
9

monitoring (MRM). The protonated parent ion [M + H]+ and daughter ions were
monitored for transitions m/z 403.22 > 268.27 and 403.22 > 224.97. WA475, internal
standard, was monitored for transition m/z 406.23 > 161.08. The MS parameters were
tuned to optimize the molecular ion signal. Spray voltage, tube lens offset, and skimmer
offset were set at 3500, 127, and 0 V. Sheath gas pressure, ion sweep gas pressure, and
aux gas pressure were optimized to 40, 0, and 5 psi, respectively. Capillary temperature
was set to 325C.
2.2.2

Method development on Waters UPLC-MS/MS systems

Chromatographic separations were carried out on Acquity ultra-high performance liquid
chromatography system (Waters, Milford, MA, USA) equipped with a binary solvent
manager, vacuum degasser, thermostatted column compartment and an auto-sampler. A
Waters Acquity UPLC CSH C18 column (1.7 L, 2.1 x 100 mm; Milford, MA, USA)
was used for chromatographic separations. A gradient method (Table 1) using aqueous
ammonium formate buffer (5 mM, 0.25% v/v formic acid) and acetonitrile was applied
for chromatographic separation. The mobile phase was pumped at a flow rate of 0.28
mL/min for a run time of 4.0 minutes. The column temperature was maintained at 40oC
and the sample temperature was maintained at 10oC. Injection volume was 2 L. Two
washes were used in between runs: strong needle wash (80:20 acetonitrile: water) and
weak needle wash (20:80 acetonitrile: water).
Time (min)
0
0.8
2.2
3.2
3.4

%A
90
90
5
5
95

%B
10
10
95
95
5

10

Curve
0
6
6
6
6

4.0
Table 3.UP LC-MS/MS Gradient 2

95

5

6

*A- ammonium formate buffer (5 mM, 0.25% formic acid v/v) *B- acetonitrile

Mass spectrometric analysis was performed using Xevo TQ-S Micro (Waters, Milford,
MA, USA) equipped with an ESI source. The detection was achieved with ESI positive
ionization using multiple reaction monitoring. The protonated parent ion [M + H]+ and
daughter ions were monitored for transitions m/z 403.20 > 268.15 and 403.22 > 225.04.
CM398 was used as an internal standard for all analyses on Waters instrumentation due
to better signals and method compatibility. IS was monitored for transition m/z 396.14 >
232.10. The following MS parameters were tuned for optimization of the signal.
Capillary voltage was set to 0.5 kV. Source temperature and desolvation temperature
were set to 150 and 500C, respectively. Cone gas flow and desolvation gas flow were
set to 50 and 900 L/h, respectively.
2.3 Preparation of calibration standards
Initial stock solution of JY08 and IS (WA475, CM398) were prepared in methanol to
yield concentrations of 1 mg/mL. Appropriate volumes of stock solutions were serially
diluted with methanol to obtain working standard solutions of JY08 and IS ranging from
20 to 4000 ng/mL. The working standard solutions were stored at -20oC.
For calibration standards, samples at 1, 2.5, 10, 50, 100, and 190 ng/mL were prepared by
2 L of the appropriate stock to 198 L of 2:1 0.02% v/v TFA in methanol: 0.02% v/v
TFA in water containing IS (3 ng/mL) for a total volume of 200 L.
For pharmacokinetic sample analysis, calibration standard samples at concentrations of 1,
2.5, 5, 25, 50, 100, 190 and 200 ng/mL were prepared by spiking 1 L of the appropriate
stock to 19 L of rat plasma.
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2.4 Plasma sample clean-up
The rat plasma samples were stored after collection at -80oC and thawed at room
temperature prior to analysis. Protein precipitation with acetonitrile containing the IS
(CM398, 20 ng/mL) and formic acid (0.25% v/v) was used for the extraction of JY08
from rat plasma samples. An aliquot of 20 L of plasma was quenched with 100 L of
quenching solution. Samples were vortexed for 10 minutes at 2000 rpm on a
BenchMixer multi-tube vortex mixer (Benchmark, San Fransisco, CA, USA). Samples
were then centrifuged at 4C for 10 minutes at 15000 rpm using Eppendorf centrifuge
5427-R (Eppendorf, Hauppauge, NY, USA). A fixed aliquot (~80 L) of the supernatant
was then taken from centrifuged samples for analysis via UPLC-MS/MS.
2.5 Solubility studies
The most common route of administration for drugs is oral ingestion (20). Oral
bioavailability is dependent on several factors including aqueous solubility, dissolution,
and first-pass metabolism (20). Thus, solubility studies are utilized to determine if
compounds are sufficient candidates for oral administration by examining the aqueous
solubility at physiological pH.
Solubility of JY08 was determined in phosphate buffer at a pH of 7.4 (n=2). Stock
solution of JY08 13 mg/mL was made fresh in potassium phosphate buffer (0.1 M, pH
7.4, 100 L). Samples were placed on a tube revolver for 24 hours at room temperature
(25C). After 24 h, samples were centrifuged and the supernatant was collected. This
supernatant was then diluted three times. For a dilution factor of 1000, supernatant (2
L) was added to methanol (1998 L). For a dilution of factor of 50,000, 10 L of the
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first dilution was added to methanol (490 L). For a dilution factor of 500,000, 10 L of
the second dilution was added to 90 L of methanol. Each sample was then analyzed via
UPLC-MS/MS for JY08 content.
2.6 Metabolic stability studies
Metabolic stability studies are important for the in vitro analysis of a drug’s
pharmacokinetic parameters. The liver is a primary site of drug metabolism (21). High
rates of metabolism can impact the oral bioavailability of a drug, while low rates can
impact toxicity. Metabolism in the human body primarily occurs through two phases.
Phase I modifications (hydrolysis, oxidations, reductions, etc.) are most commonly
performed by the cytochrome P450 enzymes. Phase II modifications involve conjugation
reactions performed by transferases. Phase I metabolic stability studies were conducted
on JY08 using rat liver CYP450 microsomes. Metoprolol, a compound with a welldefined metabolic profile, was used for positive and negative control samples.
To a 96-well plate, rat liver microsomes (0.5 mg/mL, 10 L) were added. TRIS buffer
(50 mM, pH 7.4, 168 L) was then added, followed by magnesium chloride in TRIS (500
mM, 20 L). NADPH (40 mM, 20 L) was added to positive controls and JY08 sample
only. The 96-well plate was then placed in an incubator held at 37C for 10 minutes.
See procedure below for specific reaction mixture.
For negative and positive control samples, metoprolol (1M, 2 L) was added to the
specified wells and placed back in the incubator. For JY08 sample, JY08 (1 M, 2 L)
was then added to the specified wells and placed back in the incubator. At the designated
time points of 0, 5, 10, 15, and 20 minutes, aliquots of 40 L were taken from each
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reaction mixture and placed in a separate 96-well plate containing a quenching solution
of ice-cold methanol with IS (3 ng/mL WA475). Samples were then centrifuged at
12000 rpm for 15 minutes. The supernatant (50 L) was collected and added to 100 L
of 0.02% v/v TFA in water for analysis via LC-MS.
2.7 Pilot pharmacokinetic study of JY08 in rats
Pharmacokinetic animal studies were performed using cannulated, male Sprague-Dawley
rats (n=2) obtained from Envigo (East Millstone, NJ, USA) with an average body weight
of 240.5  12 g. All experimental procedures were approved and performed in
accordance with the guidelines set in place by the Institutional Animal Care and Use
Committee (IACUC) of the University of Mississippi. The rats were housed in metabolic
cages and allowed free movement and access to water throughout the experiment. Rats
were fasted 12-15 hours prior to the experiment. For pilot studies, both single oral dosing
(20 mg/kg) and IV bolus (1 mg/kg) of JY08 (n=1, each) was tested.

The oral dose was

prepared by dissolving JY08 (41.3 mg) in distilled water (7 mL) and administered as a
weight-based dose using an oral gavage syringe. IV bolus dose was prepared by
dissolving JY08 (3 mg) in saline (3 mL) and injected through the caudal vein. Sample
collection for IV was performed at pre-dose and 5 min, 10 min, 20 min, 30 min, 45 min,
1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h post-dose. For oral pharmacokinetic study, blood
samples were collected pre-dose and 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h,
and 24 h post-dose. At each time point, 0.1 mL of blood was taken from each animal
using a fresh syringe. Following each collection, cannulas were flushed with 0.1 mL of
heparinized saline. Blood samples were collected in micro-centrifuged tubes and

14

centrifuged for 10 minutes to separate plasma and cell components. Plasma was then
placed into a clean tube and stored at -80C until analyzed.
2.8 Full pharmacokinetic study of JY08 in rats
Pharmacokinetic animal studies were performed using cannulated, male Sprague-Dawley
rats received from Envigo (East Millstone, NJ, USA) with an average body weight of 275
 25 g. All experimental procedures were approved and performed in accordance with
the guidelines set in place by the Institutional Animal Care and Use Committee (IACUC)
of the University of Florida. The rats were housed in metabolic cages and allowed free
movement and access to water throughout the experiment. Rats were fasted 15 hours
prior to the experiment. Male rats received either a single oral (n=6) or IV (n=6)
administration of the JY08 formulation. The oral dose was administered using an oral
gavage syringe. IV bolus was administered through the caudal vein. Sample collection
following single IV bolus (1 mg/kg) was performed pre-dose and 5 min, 10 min, 15 min,
20 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, and 36 h post-dose.
Sample collection following oral dosing was performed pre-dose and 5 min, 10 min, 15
min, 20 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-dose. Please note that
blood volume taken from each animal did not exceed 10% of the total blood volume for
each animal. At each time point, approximately 0.1 mL of blood was sampled from each
animal using a fresh syringe. Following each collection, cannulas were flushed with 0.1
mL of heparinized saline. Blood samples were collected in micro-centrifuged tubes and
centrifuged for 10 minutes to separate plasma and cell components. Plasma was then
collected and stored at -80C until analyzed.
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2.9 Pharmacokinetic analysis
Data analysis of pharmacokinetic studies was performed with Phoenix Software (Certara
Inc., MO, USA) using non-compartmental analysis. Concentration-time data and
pharmacokinetic parameters are represented as mean  standard error mean (SEM). Peak
plasma concentration (C max) and time to reach peak concentration (T max) were determined
based on concentration-time data. Area under the plasma concentration-time curve from
0 to last measured concentration (AUClast) was calculated through the linear trapezoidal
method. Half-life (t1/2) was calculated as a function of the slope (elimination constant)
from the plotted curves.
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3.

RESULTS AND DISCUSSION

3.1 UPLC-MS/MS optimization
3.1.1

Thermo Scientific

Positive electrospray ionization of JY08 and WA475 produced their respective molecular
ions [M + H+] at m/z 403.22 and 406.23. Capillary voltage (3.5 kV), tube lens offset (127
V), capillary temperature (325 oC) and sheath gas pressure (40 psi) were tuned to obtain
the most intense signal for both compounds. Fragmentation produced several daughter
ions for JY08 and IS, establishing qualitative and quantitative ions for monitoring
transitions.
Compound

Ions

Dwell
(sec)

Cone
Voltage

JY08- Qualitative
JY08- Quantitative
WA475- IS

403.22 > 268.27
403.22 > 224.97
406.23 > 161.08

0.21
0.21
0.21

88.0
88.0
70.0

Collison
Energy
Voltage
25.0
28.0
34.0

Table 4. MS Parameters for JY08 and WA475

During chromatographic method development, both isocratic and gradient methods were
explored with the intent to develop a quick, efficient method with optimal retention times
and peak shapes for both JY08 and IS. Various chromatographic conditions were
employed using multiple columns (Acquity UPLC BEH C18, CSH C18, Cyano, Phenyl
Hexyl) and mobile phase compositions (methanol, acetonitrile, formic acid, and
ammonium acetate buffer) in both gradient and isocratic methods. It was determined that
an Acquity UPLC CSH C18 column and a gradient mobile phase of 0.1% v/v formic acid
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in water and methanol optimized the chromatographic separation of both JY08 and
WA475 (IS). Retention times for JY08 and WA475 were 2.40 and 2.65 minutes,
respectively. This method produced sharp, clean peaks allowing for a LOD of 1 ng/mL.
3.1.2 Waters
The electrospray ionization of JY08 and the IS produced their respective protonated
molecular ions, [M + H]+, at m/z 403.20 and 396.14 under positive ionization mode. To
obtain the most intense molecular ion signal, several source parameters were optimized.
These include capillary voltage (0.5 kV), source temperature (150oC), desolvation
temperature (500oC), cone gas flow (50 L/hr), and desolvation gas flow (900 L/hr). The
protonated molecular ions of each compound undergo fragmentation in the collision cell
of the mass spectrometer. Several daughter ions are produced from each compound and
those with the greatest abundance and stability are selected for monitoring transitions.
Fragment ions m/z 268.15 and m/z 225.04 were selected as the qualitative and
quantitative transitions for JY08, respectively. Fragment ion m/z 232.10 of the IS was
selected. Several parameters were optimized to both compounds and their fragment ions
as described below in Table 5.
Compound

Ions

Dwell
(sec)

Cone
Voltage

JY08- Qualitative
JY08- Quantitative
CM398- IS

403.20 > 268.15
403.20 > 225.04
396.14 > 232.10

0.110
0.110
0.110

88.0
88.0
70.0

Table 5. MS Parameters for JY08 and CM398

18

Collison
Energy
Voltage
28.0
28.0
26.0

A

B

Figure 2. MRM spectra of (A) JY08 and (B) internal standard CM398.

Chromatographic analysis of JY08 and the IS was initiated with the intent to develop a
simple method with clean separation in a short run time. Various chromatographic
conditions were tested using various columns (Acquity UPLC CSH and BEH C18) and
mobile phase compositions (methanol, acetonitrile, formic acid, ammonium acetate, and
ammonium formate buffers) in both gradient and isocratic methods. It was determined
that an Acquity UPLC CSH C18 column and a gradient mobile phase of 0.25% formic
acid in 5 mM ammonium formate buffer and acetonitrile optimized the chromatographic
separation of both JY08 and the IS. Retention times for JY08 and CM398 were 1.87 and
1.91 minutes, respectively. This method produced sharp, clean peaks allowing for a LOD
of 1 ng/mL.
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Figure 2. Representative MRM Chromatograms of (A) JY08 Quantifier Ion (B) JY08 Qualifier Ion (C) CM398

3.2 Calibration curve
Calibration standards 1, 2.5, 5, 25, 50, 100, 190 and 200 ng/mL were run using UPLCMS Gradient 1 (Table 3). Calibration curve was constructed by plotting the peak area
ratio of JY08 to that of IS against the corresponding nominal concentration. The linear
regression equation of the calibration curve obtained from 8 points was y = 0.0785x +
0.0183. Correlation coefficient was always ≥0.99 during the analysis.

Graph 1. JY08 Calibration Curve in Rat Plasma

3.3 Solubility studies
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The calculated solubility of JY08 at a pH of 7.4 is 3.75 mg/mL. The United States
Pharmacopeia states that a substance is “slightly soluble” if 100-1000 parts of solvent are
required to dissolve 1 part of solute (20). Thus, JY08 can be classified as slightly
soluble. These values indicate JY08 partly in an ionized state at pH 7.4. The extent of
ionization of a drug will determine the amount of absorption at a given pH within the
body. Thus, at a physiological pH of 7.4, only unionized drug will be absorbed.
3.4 Metabolic stability studies
Metabolic stability samples were run on Thermo Scientific instrumentation using gradient
method 1. The area under the curve (AUC) of each sample was used to calculate the
percent remaining of each compound, using the IS (WA475) AUC as reference. The
JY08 sample exhibited odd metabolism patterns, with an increase in concentration for
three time points. This is most likely due to instrumentation or procedure error.
However, repeated studies (not shown) displayed the same metabolic pattern. This
metabolic pattern may indicate a slow metabolism of JY08 by CYP450 enzymes or
primary metabolism of JY08 occurs by phase II enzymes. Positive control metoprolol
sample exhibited a normal metabolism pattern, indicating that reaction components and
enzymes were working properly. Negative control metoprolol sample was expected to
stay at 100% throughout all time points; however, the decreases in concentration
observed can be attributed to non-specific binding of compound to enzyme. Because of
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the problems that occurred with this study, the phase I metabolic studies will be repeated
by the Avery group at a later date.

Graph 2. Phase I Metabolic Stability of JY08

Time (minutes)
0
5
10
15
20

% remaining
JY08
100
118.30
137.75
121.75
92.32

% remaining
Metoprolol (NC)
100
84.80
79.92
81.54
78.88

% remaining
Metoprolol (PC)
100
59.39
44.12
41.25
38.66

Table 6. Measured Metabolism in Rat Liver Microsomes

3.5 Pilot pharmacokinetic study
Following IV dosing in Sprague Dawley rats (n=1), JY08 exhibited biphasic and
extravascular distribution with a volume of distribution (Vd) of 26.3 L/kg. This volume
of distribution is larger than the total blood volume in rats (0.085 L/kg) (22). IV
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injections follow multiphasic absorption patterns in which there are two phases. In the
alpha phase, drug distribution shifts from systemic circulation (central compartment) to
body tissues and organs (peripheral compartment). In the alpha phase, absorption is
greater than elimination. In the beta phase, elimination is greater than absorption and a
decrease in plasma drug concentration is seen due to metabolism and excretion
mechanisms. Extra-hepatic metabolism and elimination was determined to be negligible
with a clearance (CL) of 2.0 L/h/kg compared to average hepatic blood flow of 4.8
L/h/kg in rats (23).
The rat receiving an oral dose of JY08 (n=1) also displayed extensive extravascular
distribution as indicated with a calculated Vd of 26.3 L/kg. The study also displayed
quick absorption, distribution, and elimination of JY08 from plasma and an oral
bioavailability of 13.9%. The concentration-time curves resulting from the oral
pharmacokinetic study of JY08 display multiple peak phenomenon (Graph 3). Oral
concentration-time curves typically exhibit an initial absorption phase in which an
increase in concentration is seen following administration as the drug enters systemic
circulation. Multiple peaks in the curve may indicate multiple absorption phases of the
compound occurring in the animal. Multiple peak phenomenon can be due to
enterohepatic recirculation, gastrointestinal recirculation, delayed gastric emptying,
and/or absorption differences in the intestines (24). Since multiple peaks are not apparent
in the IV concentration-time curve, enterohepatic circulation is probably not the cause of
the multiple absorption phases. This phenomenon could possibly be due to the multiple
pKa points displayed by JY08. Drugs are only absorbed in unionized states. Thus, as the
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surrounding pH changes throughout the GIT, JY08 will experience different ionization
states causing discontinuous absorption.
After oral and IV dosing, mean residence time (MRT) for JY08 was found to be 6.4 and
4.9 h, respectively. MRT is used to represent the average amount of time the drug stays
in a body. Since drugs administered intravenously do not undergo an absorption phase, it
is expected for the residence time of IV administered drugs to be shorter than oral drugs.
This concept applies to terminal half-life (t1/2) as well (25).
Parameters
Cmax1 (ng/mL)
Cmax2 (ng/mL)
Tmax1 (h)
Tmax2 (h)
AUC (ng•h/mL)
MRT (h)
T1/2 (h)
Vd (L/kg)
Clearance (L/h/kg)
Bioavailability (%)

Oral
174.9
158.4
0.5
2.0
1357.5
6.4
11.33
34.1
2.1
13.9

Table 7. Pharmacokinetic Parameters of JY08 Pilot Study
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Intravenous
0
489.5
4.9
8.93
26.3
2.0
-

Graph 3. Pilot Oral Pharmacokinetic Study of JY08

Graph 4. Pilot IV Pharmacokinetic Study of JY08

3.6 Full pharmacokinetic study
The full PK studies of JY08 in rats produced similar results to pilot studies. With a
volume of distribution (Vd) of 20.4  4.3 and 32.8  6.8 L/kg for oral and IV doses,
respectively, JY08 is extensively distributed in extra-vascular systems. Extra-hepatic
metabolism and elimination were negligible with clearances (CL) of 1.1  0.2 and 1.2 
0.2 L/h/kg for oral and IV, respectively. Similar to pilot study results, oral bioavailability
was determined to be low at 9.1%. This low range may be due to first pass metabolism
or poor absorption of JY08 in the gastrointestinal tract (25). Concentration-time curves
of the oral pharmacokinetic study of JY08 display multiple peak phenomenon as also
seen in the pilot study. The Cmax and Tmax for each absorption phase is listed in Table 8.
The terminal half-life for oral and IV doses was 13.6  2.7 and 32.8  6.8, respectively.
Parameters
Cmax1 (ng/mL)

Oral
217.5  40.0
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Intravenous
-

Cmax2 (ng/mL)
Tmax1 (h)
Tmax2 (h)
AUC (ng•h/mL)
T1/2 (h)
Vd (L/kg)
Clearance (L/h/kg)
Bioavailability (%)

210.1  36.1
0.4  0.1
2.8  0.6
1788.5  265.1
13.6  2.7
20.4  4.3
1.1  0.2
9.1

988.1  158.3
21.6  3.7
32.8  6.8
1.2  0.2
-

Table 8. Pharmacokinetic Parameters of JY08 Full Study

Graph 6. IV Pharmacokinetic Study of JY08

Graph 5. Oral Pharmacokinetic Study of JY08

3.7 Putative metabolites of JY08
Using MetaboLynx software, metabolites of JY08 from in vivo plasma samples were
identified via mass spectrometry. Phase I metabolism includes oxidation, reduction,
hydrolysis, and dealkylation. As depicted in Figure X, both metabolites 1 and 3
underwent dealkylation reactions by phase I enzymes. Metabolite 4 underwent a
hydroxylation reaction. In metabolite 2, the guanidine group of JY08 was cleaved. Other
metabolites that are conjugation products were also present in lower abundance.

26

Analyzing the possible biotransformation routes of JY08 can reveal metabolic “weak
spots” in compound structure that can be modified through drug design to develop a more
successful drug in vivo.

Figure 3. Putative Metabolites of JY08
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4.

CONCLUSION

With the rapidly evolving opioid crisis and limited long-term analgesic therapies, there is
a major need for the development of opioids that can combat the tolerance and
hyperalgesia commonly experienced with long-term use of opioids. JY08, developed as a
dual activity ligand at the mu-opioid receptor and neuropeptide FF receptor, has the
potential to serve as a safer, more effective treatment for pain.
The pharmacokinetic principles of absorption, distribution, metabolism, and excretion
were analyzed to determine the physiochemical properties of JY08 in vitro and in vivo. A
simple and sensitive UPLC-MS method was developed for the analysis of these studies.
A simple and efficient extraction method was developed for plasma sample preparation
that required low plasma volumes, enabling repeated sampling in rodents.
The results of ADME studies determined that JY08 is quickly absorbed in rats. Single
dose oral and IV pharmacokinetic studies revealed extensive extravascular distribution.
In vitro metabolic studies were inconclusive but can be repeated to determine the primary
pathway of metabolism of JY08. In vivo studies showed that JY08 is primarily
dependent on hepatic elimination. When JY08 is dosed orally in rats, it exhibits multiple
absorption phases and low oral bioavailability, most likely due to first pass effect or poor
absorption. Though bioavailability is low, the pharmacokinetic profile of JY08 with a
large volume of distribution and long half-life support the potential of JY08 as a drug
candidate for the treatment of pain in the clinical setting.
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